Glivec Research Today is a free monthly online journal that collates and summarizes the latest research about Glivec, including details on gleevec, imatinib, cancer, treatment, side-effects.

Volume 3 (2006), Issue 5 (May)

1. Inhibition of phosphorylation of the colony-stimulating factor-1 receptor (c-Fms) tyrosine kinase in transfected cells by ABT-869 and other tyrosine kinase inhibitors.
   Mol Cancer Ther, 5(4): 1007-13. [Abstract] [Full-text]
2. Increased sensitivity to the platelet-derived growth factor (PDGF) receptor inhibitor STI571 in chemoresistant glioma cells is associated with enhanced PDGF-BB-mediated signaling and STI571-induced Akt inactivation.
   J Cell Physiol, 208(1): 220-8. [Abstract] [Full-text]
3. Multiple joint effusions associated with high-dose imatinib therapy in a patient with chronic myelogenous leukaemia.
   Eur J Haematol, 76(5): 444-6. [Abstract] [Full-text]
4. Inducible activation of CEBPB, a gene negatively regulated by BCR/ABL, inhibits proliferation and promotes differentiation of BCR/ABL-expressing cells.
   Blood, 107(10): 4080-9. [Abstract] [Full-text]
5. In vitro validation of bioluminescent monitoring of disease progression and therapeutic response in leukaemia model animals.
   Eur J Nucl Med Mol Imaging, 33(5): 557-65. [Abstract] [Full-text]
6. Risk stratification, staging, and treatment of patients with polycythemia vera: Italian and European collaboration on low-dose aspirin in polycythemia data.
   Semin Thromb Hemost, 32(3): 276-82. [Abstract] [Full-text]
7. Selective kinase inhibition with daily imatinib intensifies toxicity of chemotherapy in patients with solid tumours.
   Eur J Cancer, 42(7): 864-70. [Abstract] [Full-text]
8. Emergence of chronic myelogenous leukemia in a patient with primary thrombocythemia and absence of BCR/ABL rearrangement.
   Cancer Genet Cytogenet, 167(1): 74-7. [Abstract] [Full-text]
9. Eosinophilia: secondary, clonal and idiopathic.
   Br J Haematol, 133(5): 468-92. [Abstract] [Full-text]
10. Loss of p53 impedes the antileukemic response to BCR-ABL inhibition.
    Proc Natl Acad Sci U S A, 103(19): 7444-9. [Abstract] [Full-text]
11. A Src-like inactive conformation in the abl tyrosine kinase domain.
    PLoS Biol, 4(5): e144. [Abstract] [Full-text]
12. In vivo effects of imatinib mesylate on human haematopoietic progenitor cells.
    Eur J Clin Invest, 36(6): 402-8. [Abstract] [Full-text]
13. Altered bone and mineral metabolism in patients receiving imatinib mesylate.
    N Engl J Med, 354(19): 2006-13. [Abstract] [Full-text]
14. Tyrosine kinase modulation of protein kinase C activity regulates G protein-linked Ca(2+) signaling in leukemic hematopoietic cells.
    Cell Calcium, 39(6): 517-28. [Abstract] [Full-text]
15. Reclassification of a tubal leiomyosarcoma as an eGIST by molecular evaluation of c-KIT.
    Gynecol Oncol, 101(2): 363-6. [Abstract] [Full-text]
16. Evaluation of imatinib mesylate effects on glioblastoma aggressiveness with SPECT radiotracer (99m)Tc-(v)-DMSA.
    Eur J Cancer, 42(8): 1004-13. [Abstract] [Full-text]
17. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours.
    Eur J Cancer, 42(8): 1093-103. [Abstract] [Full-text]
18. RECIST revisited: A review of validation studies on tumour assessment.
    Eur J Cancer, 42(8): 1031-9. [Abstract] [Full-text]
19. Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients.
    Clin Cancer Res, 12(10): 3037-42. [Abstract] [Full-text]
20. Therapeutic effect of imatinib in gastrointestinal stromal tumors: AKT signaling dependent and independent mechanisms.
    Cancer Res, 66(10): 5477-86. [Abstract] [Full-text]
21. Resistance to imatinib of bcr/abl p190 lymphoblastic leukemia cells.
    Cancer Res, 66(10): 5387-93. [Abstract] [Full-text]
22. Imatinib-associated neutropenia may not be overcome by filgrastim treatment in patients with blastic phase of chronic myeloid leukaemia.
    Clin Lab Haematol, 28(3): 208-10. [Abstract] [Full-text]
23. Inhibition of SCF attenuates peribronchial remodeling in chronic cockroach allergen-induced asthma.
    Lab Invest, 86(6): 557-65. [Abstract] [Full-text]
24. Zoledronic Acid (Zometa) Enhances the Cytotoxic Effect of Gemcitabine and Fluvastatin: In vitro Isobologram Studies with Conventional and Nonconventional Cytotoxic Agents.
    Oncology, 70(2): 147-53. [Abstract] [Full-text]
25. Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors.
    J Clin Oncol, 24(15): 2325-31. [Abstract] [Full-text]
26. Imatinib as a potential antiresorptive therapy for bone disease.
    Blood, 107(11): 4334-7. [Abstract] [Full-text]
27. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction.
    Blood, 107(11): 4532-9. [Abstract] [Full-text]
28. BCR-ABL mRNA levels at and after the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib mesylate-treated patients with CML.
    Blood, 107(11): 4250-6. [Abstract] [Full-text]
29. Identification of genes involved in imatinib resistance in CML: a gene-expression profiling approach.
    Leukemia, 20(6): 1047-54. [Abstract] [Full-text]
30. BCR-ABL activity and its response to drugs can be determined in CD34+ CML stem cells by CrkL phosphorylation status using flow cytometry.
    Leukemia, 20(6): 1035-9. [Abstract] [Full-text]
31. Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi(phi)-LMC GROUP).
    Leukemia, 20(6): 1061-6. [Abstract] [Full-text]
32. Gene expression profiling of CD34+ cells identifies a molecular signature of chronic myeloid leukemia blast crisis.
    Leukemia, 20(6): 1028-34. [Abstract] [Full-text]
33. New developments in gastrointestinal stromal tumor.
    Curr Opin Oncol, 18(4): 386-95. [Abstract] [Full-text]
34. Mammalian target of rapamycin inhibitors in sarcomas.
    Curr Opin Oncol, 18(4): 360-2. [Abstract] [Full-text]
35. Dermatofibrosarcoma protuberans: a surgical disease with a molecular savior.
    Curr Opin Oncol, 18(4): 341-346. [Abstract] [Full-text]
36. A case of c-kit positive high-grade stromal endometrial sarcoma responding to Imatinib Mesylate.
    Gynecol Oncol, 101(3): 545-7. [Abstract] [Full-text]
37. The role of imatinib mesylate (Glivec) for treatment of patients with malignant endocrine tumors positive for c-kit or PDGF-R.
    Endocr Relat Cancer, 13(2): 535-40. [Abstract] [Full-text]
38. Targeting tyrosine kinases in cancer: the second wave.
    Science, 312(5777): 1175-8. [Abstract] [Full-text]
39. An update on molecular genetics of gastrointestinal stromal tumours.
    J Clin Pathol, 59(6): 557-63. [Abstract] [Full-text]
40. Ph-positive acute lymphoblastic leukemia after long-term remission of Ph-positive acute myeloid leukemia.
    Leuk Res. [Abstract] [Full-text]
41. Management of metastatic gastrointestinal stromal tumour in the Glivec era: a practical case-based approach.
    Intern Med J, 36(6): 367-77. [Abstract] [Full-text]

© 2004-2008 Glivec Research Today. All Rights Reserved.